{"id":"atg-csa","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Cytopenias (thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neurotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3038082","moleculeType":"Protein","molecularWeight":"1361.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG is a polyclonal antibody that binds to and depletes T lymphocytes, reducing the cellular immune response. Cyclosporine A inhibits calcineurin, blocking T cell receptor signaling and IL-2 production. Combined, they provide potent immunosuppression used primarily in transplantation and severe autoimmune conditions.","oneSentence":"ATG (antithymocyte globulin) and CSA (cyclosporine A) together provide immunosuppression by depleting T cells and inhibiting T cell activation, respectively.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:51.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease (GVHD) prevention or treatment"},{"name":"Hematopoietic stem cell transplantation conditioning"}]},"trialDetails":[{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT04304820","phase":"PHASE2","title":"Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-05-07","conditions":"Severe Aplastic Anemia","enrollment":80},{"nctId":"NCT07440654","phase":"NA","title":"Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-03-01","conditions":"aGVHD Prophylaxis","enrollment":40},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT02203396","phase":"PHASE2","title":"A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2014-08","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT05166967","phase":"PHASE3","title":"Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-01-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":204},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":"Aplastic Anemia, Cytopenia, Hypocellular Marrow","enrollment":35},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT06650553","phase":"NA","title":"Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2024-06-01","conditions":"Aplastic Anemias","enrollment":110},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT07010237","phase":"PHASE2","title":"Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-02-01","conditions":"Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment","enrollment":65},{"nctId":"NCT06991894","phase":"","title":"Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-14","conditions":"Anemia, Aplastic","enrollment":2517},{"nctId":"NCT06869265","phase":"PHASE2","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-01","conditions":"Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":56},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT05996393","phase":"PHASE4","title":"CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-15","conditions":"Aplastic Anemia","enrollment":86},{"nctId":"NCT06949267","phase":"EARLY_PHASE1","title":"A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Acute Graft-versus-Host Disease","enrollment":56},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT01623167","phase":"PHASE1, PHASE2","title":"Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2012-07-02","conditions":"Severe Aplastic Anemia","enrollment":207},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT02274662","phase":"PHASE4","title":"Expanded Access Protocol Thymus Transplantation","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2014-08","conditions":"Poor Thymic Function, Immunodeficiency, Athymia","enrollment":11},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT06512545","phase":"NA","title":"Modified Second Haplo-transplantation for Graft Failure","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Graft Failure, Stem Cell Transplant Complications","enrollment":12},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06378060","phase":"PHASE2","title":"Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Hematology department of the 920th hospital","startDate":"2024-03-01","conditions":"Severe Aplastic Anemia","enrollment":30},{"nctId":"NCT01163942","phase":"PHASE3","title":"Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2001-03","conditions":"Aplastic Anaemia","enrollment":205},{"nctId":"NCT02998645","phase":"PHASE2","title":"Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-11","conditions":"Severe Aplastic Anemia","enrollment":54},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT00471848","phase":"PHASE2","title":"Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2008-08","conditions":"Aplastic Anemia","enrollment":35},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT00003838","phase":"PHASE2","title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-04-15","conditions":"Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia","enrollment":202},{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210},{"nctId":"NCT00325741","phase":"PHASE1","title":"Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Stanford University","startDate":"2004-06","conditions":"Lupus Erythematosus, Systemic","enrollment":1},{"nctId":"NCT01231841","phase":"PHASE2","title":"Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2005-03","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT00074269","phase":"PHASE2","title":"Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2003-07","conditions":"Breast Cancer","enrollment":5},{"nctId":"NCT00896493","phase":"PHASE2","title":"Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous","enrollment":38},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT04778618","phase":"PHASE2","title":"Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":63},{"nctId":"NCT02745717","phase":"PHASE4","title":"The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT04688021","phase":"PHASE2","title":"A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.","status":"UNKNOWN","sponsor":"Yi Luo","startDate":"2020-12-03","conditions":"Leukemia, Graft-versus-host-disease","enrollment":46},{"nctId":"NCT05634915","phase":"PHASE4","title":"Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-20","conditions":"Hematopoietic Stem Cell Transplantation, Acute Leukemia","enrollment":90},{"nctId":"NCT02623309","phase":"PHASE3","title":"Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2016-02-23","conditions":"Hematologic Neoplasms","enrollment":108},{"nctId":"NCT01811368","phase":"PHASE2","title":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Joseph Tuscano","startDate":"2013-03-12","conditions":"Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT05571332","phase":"NA","title":"Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-28","conditions":"Aplastic Anemia","enrollment":39},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02677181","phase":"PHASE4","title":"Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2016-01","conditions":"aGVHD","enrollment":100},{"nctId":"NCT00566488","phase":"PHASE1","title":"Parathyroid and Thymus Transplantation in DiGeorge #931","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-01","conditions":"DiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge Syndrome","enrollment":25},{"nctId":"NCT00849888","phase":"PHASE1","title":"Serum-Free Thymus Transplantation in DiGeorge Anomaly","status":"TERMINATED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2008-04","conditions":"DiGeorge Anomaly","enrollment":2},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT05214066","phase":"PHASE2","title":"Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2019-02-01","conditions":"aGVHD, cGVHD","enrollment":60},{"nctId":"NCT00630253","phase":"PHASE1, PHASE2","title":"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-02-17","conditions":"Fanconi Anemia","enrollment":31},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT05049668","phase":"","title":"RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial","status":"ENROLLING_BY_INVITATION","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2021-10","conditions":"Severe Aplastic Anemia","enrollment":197},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT00065260","phase":"PHASE2","title":"Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-11-06","conditions":"Aplastic Anemia","enrollment":54},{"nctId":"NCT00061360","phase":"PHASE2","title":"Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-06-26","conditions":"Severe Aplastic Anemia","enrollment":77},{"nctId":"NCT03602898","phase":"PHASE2","title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-01","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":""},{"nctId":"NCT04945096","phase":"PHASE3","title":"Outcomes of Patients After Allo-HSCT With Decitabine and NAC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-07-01","conditions":"Engraft Failure, Relapse, GVHD","enrollment":100},{"nctId":"NCT00185640","phase":"PHASE2","title":"Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Stanford University","startDate":"2003-03","conditions":"Blood Cancer, Leukemia","enrollment":303},{"nctId":"NCT02424968","phase":"PHASE2","title":"CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Robert Lowsky","startDate":"2015-06","conditions":"Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":18},{"nctId":"NCT02707393","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children With CML","status":"COMPLETED","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2009-04-30","conditions":"Chronic Myeloid Leukemia","enrollment":13},{"nctId":"NCT00861679","phase":"NA","title":"Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2007-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":552},{"nctId":"NCT00944749","phase":"PHASE2","title":"Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-08-31","conditions":"Anemia, Aplastic, Anemia, Hypoplastic","enrollment":23},{"nctId":"NCT00886522","phase":"PHASE2","title":"Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2009-04","conditions":"Hematological Malignancies","enrollment":23},{"nctId":"NCT00001964","phase":"PHASE2","title":"Combination Therapy of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2000-03-17","conditions":"Severe Aplastic Anemia","enrollment":104},{"nctId":"NCT03413306","phase":"PHASE3","title":"Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2016-12-10","conditions":"Acquired Aplastic Anemia","enrollment":100},{"nctId":"NCT02462252","phase":"PHASE2","title":"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2015-10","conditions":"Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT02099747","phase":"PHASE3","title":"hATG+CsA vs hATG+CsA+Eltrombopag for SAA","status":"COMPLETED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2015-07","conditions":"Severe Aplastic Anemia","enrollment":202},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT01856803","phase":"PHASE4","title":"Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2013-10","conditions":"Leukemia, GVHD, ATG, Transplantation","enrollment":300},{"nctId":"NCT00001626","phase":"PHASE2","title":"Comparing Therapies for the Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1997-06-02","conditions":"Severe Aplastic Anemia (SAA)","enrollment":33},{"nctId":"NCT03955601","phase":"PHASE2","title":"A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:","status":"UNKNOWN","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2018-07-12","conditions":"Aplastic Anemia Idiopathic","enrollment":30},{"nctId":"NCT00068523","phase":"NA","title":"Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2003-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":10},{"nctId":"NCT00303719","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Kidney Cancer, Leukemia, Lymphoma","enrollment":342},{"nctId":"NCT00553202","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01","conditions":"Leukemia","enrollment":158},{"nctId":"NCT02487069","phase":"NA","title":"Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2015-06","conditions":"Acute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":876},{"nctId":"NCT00854139","phase":"PHASE1","title":"Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2001-08","conditions":"Multiple Myeloma, End Stage Renal Disease","enrollment":10},{"nctId":"NCT00006451","phase":"PHASE3","title":"Bone Marrow Transplantation in Treating Patients With Leukemia","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1996-04","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT04203108","phase":"PHASE4","title":"ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-09-01","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":266},{"nctId":"NCT00003270","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1997-09-04","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ATG + CSA","genericName":"ATG + CSA","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATG (antithymocyte globulin) and CSA (cyclosporine A) together provide immunosuppression by depleting T cells and inhibiting T cell activation, respectively. Used for Graft-versus-host disease (GVHD) prevention or treatment, Hematopoietic stem cell transplantation conditioning.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}